Vamsi Vasireddy, DO
Medical Oncology · Urbana, ILNPI 1801802996
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 121 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$526
- Merck$395
- Johnson & Johnson$358
- Pfizer$181
- Daiichi Sankyo Inc.$142
- Genentech USA, Inc.$89
- plus $1K from 30 others
Across 38 payments — averaging $3820.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$80K
- AstraZeneca$28K
- Eli Lilly$26K
- Incyte Corporation$9K
- F. Hoffmann-la Roche AG$3K
- Merck$423
What the payments were for
- Food & beverage$2,53591%
- Education$2659%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $526 |
| Merck | 19 | $395 |
| Johnson & Johnson | 6 | $358 |
| Pfizer | 12 | $181 |
| Daiichi Sankyo Inc. | 7 | $142 |
| Genentech USA, Inc. | 6 | $89 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $85 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Janssen Scientific Affairs, LLC | 1 | $75 |
| Array Biopharma Inc | 3 | $72 |
| AbbVie | 2 | $62 |
| Eisai Inc. | 3 | $52 |
| Exelixis Inc. | 3 | $52 |
| Novartis | 2 | $50 |
| Gilead | 2 | $48 |
| Bristol Myers Squibb | 3 | $47 |
| Astellas Pharma US Inc | 2 | $45 |
| Ipsen Biopharmaceuticals, Inc | 3 | $45 |
| Beone Medicines USA, Inc. | 2 | $45 |
| Sanofi | 2 | $38 |
| Clovis Oncology, Inc. | 1 | $32 |
| Genmab U.S., Inc. | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Seagen Inc. | 1 | $26 |
| GSK | 1 | $23 |
| Genentech, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $16 |
| Heron Therapeutics, Inc. | 1 | $15 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $14 |
| Incyte Corporation | 1 | $13 |
| Medtronic | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,800 in reported general payments places this provider in the 60th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 59 | $855,348 |
| RevlimidLenalidomide | 51 | $716,862 |
| BrukinsaZanubrutinib | 42 | $562,985 |
| CalquenceAcalabrutinib Maleate | 33 | $539,268 |
| Lenalidomide | 42 | $527,715 |
| CabometyxCabozantinib S-Malate | 18 | $411,418 |
| LynparzaOlaparib | 21 | $356,905 |
| Abiraterone Acetate | 67 | $325,066 |
| PomalystPomalidomide | 13 | $311,157 |
| OxbrytaVoxelotor | 19 | $182,223 |
| ErleadaApalutamide | 12 | $160,670 |
| VonjoPacritinib Citrate | 11 | $154,224 |
| JakafiRuxolitinib Phosphate | 13 | $104,025 |
| InlytaAxitinib | 12 | $92,744 |
| XareltoRivaroxaban | 110 | $81,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Lynparza | $526 | $896,17354 claims |
| Astellas Pharma US IncXtandi | $45 | $855,34859 claims |
| Bristol Myers SquibbRevlimid | $47 | $716,86251 claims |
| Exelixis Inc.Cabometyx | $52 | $411,41818 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $75 | $325,06667 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $79 | $311,15713 claims |
| Johnson & JohnsonErleada, Xarelto | $358 | $241,749122 claims |
| PfizerInlyta, Eliquis | $181 | $170,107108 claims |
| Incyte CorporationJakafi | $13 | $104,02513 claims |
| AbbVieVenclexta, Creon | $62 | $35,60924 claims |
| Lilly USA, LLCOlanzapine | $20 | $60530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Urbana
- Tanmay SahaiUrbana$3K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Nicklas PfanzelterGlenview$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.